ArticleUpsala journal of medical sciences2013
Ruling out cardiac failure: cost-benefit analysis of a sequential testing strategy with NT-proBNP before echocardiography.
Article in Upsala journal of medical sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Brain natriuretic peptide and N-terminal brain natriuretic peptide for the diagnosis of haemodynamically significant patent ductus arteriosus in preterm neonates.The Cochrane database of systematic reviews · 2022Pooled it
- NT-proBNP and its correlation to left ventricular ejection fraction and heart failure - The DEMONSTRATE database.Annals of clinical biochemistry · 2026Article
- The role of NT-proBNP in screening for atrial fibrillation in hypertensive disease.International journal of cardiology. Heart & vasculature · 2024Article
- Assessment of Volume Status in Hospitalized Patients With Chronic Heart Failure.Cardiology research · 2023Review
- TheFrontiers in public health · 2018Article
- MICE or NICE? An economic evaluation of clinical decision rules in the diagnosis of heart failure in primary care.International journal of cardiology · 2017Observational
- The Clinical Significance of N-terminal Pro-brain Natriuretic Peptide in Detecting the Residual Cardiovascular Risk in Hypertension and Other Clinical Conditions and in Predicting Future Cardiovascular Events.Journal of clinical hypertension (Greenwich, Conn.) · 2016Article
- Evaluation of the Alere NT-proBNP Test for Point of Care Testing.Journal of clinical laboratory analysis · 2016Article
- Provocative biomarker stress test: stress-delta N-terminal pro-B type natriuretic peptide.Open heartArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo estimate the possible economic benefit of a sequential testing strategy with NT-proBNP to reduce the number of echocardiographies.
methodsRetrospective study in a third-party payer perspective. The costs were calculated from three Swedish counties: Blekinge, Östergötland, and Uppland. Two cut-off levels of NT-proBNP were used: 400 and 300 pg/mL. The cost-effectiveness of the testing strategy was estimated through the short-term cost avoidance and reduction in demand for echocardiographies.
resultsThe estimated costs for NT-proBNP tests and echocardiographies per county were reduced by 33%-36% with the 400 pg/mL cut-off and by 28%-29% with the 300 pg/mL cut-off. This corresponded to a yearly cost reduction of approximately €2-5 million per million inhabitants in these counties.
conclusionThe use of NT-proBNP as a screening test could substantially reduce the number of echocardiographies in the diagnostic work-up of patients with suspected cardiac failure, as well as the associated costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.